Language selection

Search

Patent 1202309 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1202309
(21) Application Number: 335522
(54) English Title: AURORE DERIVATIVES
(54) French Title: DERIVES D'AURONE
Status: Expired
Bibliographic Data
(52) Canadian Patent Classification (CPC):
  • 260/304.7
  • 260/362.8
  • 260/361.9
(51) International Patent Classification (IPC):
  • C07D 307/83 (2006.01)
  • C07C 45/63 (2006.01)
  • C07C 65/40 (2006.01)
  • C07D 257/04 (2006.01)
  • C07D 307/92 (2006.01)
  • C07D 317/30 (2006.01)
  • C07D 405/04 (2006.01)
(72) Inventors :
  • BAKER, STEPHEN R. (United Kingdom)
  • ROSS, WILLIAM J. (United Kingdom)
  • JAMIESON, WILLIAM B. (United Kingdom)
(73) Owners :
  • LILLY INDUSTRIES LIMITED (United Kingdom)
(71) Applicants :
(74) Agent: GOWLING LAFLEUR HENDERSON LLP
(74) Associate agent:
(45) Issued: 1986-03-25
(22) Filed Date: 1979-09-12
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
36705/78 United Kingdom 1978-09-13

Abstracts

English Abstract



AURONE DERIVAT IVES
ABSTRACT OF THE INVENTION

Substituted aurones ot formula (I) :


Image (I)


wherein R1, R2, R3, R4, R5 and R6 are the same or different and can
each represent hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C3-8
cycloalkyl, optionally substituted phenyl, Cl 6 haloalkyl, amido,
amino, cyano, hydroxy, nitro, C2-4 alkenyl, carboxyl, tetrazol-5-yl
and -CH_CHCOOH; or
wherein R1 and R2 taken together can represent a group of formula
-CH-CH-CH-CH- provided that at least ono of R17 R2, R3, R4, R5 and R6
is carboxyl, tetrazol-5-yl or -CH=CICOOH;
or a pharmaceutically-acceptable salt or ester thereof, are effective
in the prophylactic chemotherapy of allergic conditions such as bronchial
asthma.


Claims

Note: Claims are shown in the official language in which they were submitted.



The embodiments of the invention in which an
exclusive property or privilege is claimed are defined as
follows:
1. A process for preparing a compound of the
formula




(I)
Image




in which R1, R2 and R3 are the same or different and can
each represent hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy,
C3-8 cycloalkyl, phenyl optionally substituted with from
1 to 3 substituents selected from methyl, methoxy, halogen
and nitro, C1-6 haloalkyl, amido, amino, cyano, hydroxy,
nitro, C2-4 alkenyl, carboxyl, tetrazol-5-yl or
CH=CHCOOH; or in which R1 and R2 taken together represent
a group of formula -CH=CH-CH=CH-; and wherein R4, R5 and
R6 are the same or different and can each represent
hydrogen, halogen, C3-8 cycloalkyl, phenyl optionally
substituted with from one to three substituents selected
from methyl, methoxy, halogen and nitro, C1-6 haloalkyl,
amido, cyano, nitro, carboxyl, tetrazol-5-yl, or
-CH=CHCOOH; or a pharmaceutically acceptable salt or ester
thereof; provided that at least one of R1, R2, R3, R4, R5
and R6 is carboxyl, tetrazol-5-yl or -CH=CHCOOH;



- 27 -


and with the proviso that compounds of the formula




Image



wherein R1 is hydrogen, C1-6 alkyl or C2-C4 alkenyl and
each of R4, R5 and R6 is independently selected from
hydrogen, C1-C6 alkoxy or C1-C6 alkyl, as well as
pharmaceutically acceptable salts thereof, are excluded;
which comprises reacting a benzaldehyde of formula




Image




with a reactant selected from (a) a benzofuranone of
formula


Image



- 28 -


or (b) an .omega.-substituted acetophenone of formula



Image




wherein R1, R2, R3, R4, R5 and R6 are as previously
defined herein and in which X is a leaving group,
optionally followed, when one or more of R4, R5 and R6
is cyano, by reaction with an azide to give the
corresponding tetrazol-5-yl compound; and where
desired, forming a pharmaceutically acceptable salt or
ester of said compound of formula (I) so prepared.
2. A process according to claim 1, wherein
at least one of R1, R2 and R3 is other than hydrogen.
3. A process according to claim 2 in which
R1 is C1-4 alkyl, carboxyl or halogen, R2 and R3 are
hydrogen, R4 is carboxyl or -CH=CHCOOH, and R5 and R6
are hydrogen.



- 29 -


4. A process according to claim 2 in which
R1 is C1-4 alkyl or carboxyl, R2 and R3 are hydrogen,
R4 is carboxyl or -CH=CHCOOH, and R5 and R6 are hydrogen.
5. A process according to claim 1 wherein at
least one of R4, R5 and R6 is halogen, C3-8 cycloalkyl,
phenyl optionally substituted with from 1 to 3
substituents selected from methyl, methoxy, halogen and
nitro, C1-6 haloalkyl, amido, cyano, nitro, carboxyl,
tetrazol-5-yl or -CH=CHCOOH.
6. A process according to claim 5 in which at
least one of R1, R2 and R3 is other than hydrogen.
7. A compound of formula




(I)
Image <IMAGE<




in which R1, R2 and R3 are the same or different and can
each represent hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy,
C3-8 cycloalkyl, phenyl optionally substituted with from
1 to 3 substituents selected from methyl, methoxy, halogen
and nitro, C1-6 haloalkyl, amido, amino, cyano, hydroxy,

nitro, C2-4 alkenyl, carboxyl, tetrazol-5-yl or
CH=CHCOOH, or in which R1 and R2 taken together represent



- 30 -


a group o formula -CH=CH-CH=CH-; and wherein R4, R5 and
R6 are the same or different and can each represent
hydrogen, halogen, C3-8 cycloalkyl, phenyl optionally
substituted with from one to three substituents selected
from methyl, methoxy, halogen and nitro, C1-6 haloalkyl,
amido, cyano, nitro, carboxyl, tetrazol-5-yl, or
-CH=CHCOOH; or a pharmaceutically acceptable salt or
ester thereof; provided that at least one of R1, R2, R3,
R4, R5 and R6 is carboxyl, tetrazol-5-yl or -CH=CHCOOH;
and with the proviso that compounds of the formula



Image
Image


wherein R1 is hydrogen, C1-6 alkyl or C2-C4 alkenyl and
each of R4, R5 and R6 is independently selected from
hydrogen, C1-C6 alkoxy or C1-C6 alkyl, as well as
pharmaceutically acceptable salts thereof, are excluded;
whenever prepared by the process of claim 1 or by an
obvious chemical equivalent thereof.

8. A compound according to claim 7 wherein

at least one of R1, R2 and R3 is other than hydrogen,
whenever prepared by the process of claim 2 or by an



- 31 -



obvious chemical equivalent thereof.
9. A compound according to claim 7 in which
R1 is C1-4 alkyl, carboxyl or halogen, R2 and R3 are
hydrogen, R4 is carboxyl or -CH=CHCOOH, and R5 and R6 are
hydrogen, when prepared by the process of claim 3 or by
an obvious chemical equivalent thereof.
10. A compound according to claim 7 in which
R1 is C1-4 alkyl or carboxyl, R2 and R3 are hydrogen,
R4 is carboxyl or -CH=CHCOOH, and R5 and R6 are hydrogen,
when prepared by the process of claim 4 or by an obvious
chemical equivalent thereof.


11. A compound according to claim 7 wherein
at least one of R4, R5 and R6 is halogen, C3-8
cycloalkyl, phenyl optionally substituted with from
1 to 3 substituents selected from methyl, methoxy,
halogen and nitro , C1-6 haloalkyl, amido, cyano, nitro,
carboxyl, tetrazol-5-yl or -CH=CHCOOH, when prepared
by the process of claim 5 or by an obvious chemical
equivalent thereof.


12. A compound according to claim 7 wherein
at least one of R1, R2 and R3 is other than hydrogen
and wherein at least one of R4, R5 and R6 is halogen,
C3-8 cycloalkyl, phenyl optionally substituted with



- 32 -


from 1 to 3 substituents selected from methyl,
methoxy, halogen and nitro, C1-6 haloalkyl, amido,
cyano, nitro, carboxyl, tetrazol-5-yl or
-CH=CHCOOH, when prepared by the process of claim
6 or by an obvious chemical equivalent thereof.


-33-

Description

Note: Descriptions are shown in the official language in which they were submitted.


?2~09

-1-

~h~ invention relates to novel aurone derivatives possessing va1uab1e

pharmacological activity, a process for their production and their use as
ph~maceuticQls.
In recent years, extensive ef~orts have been made to discover new
compounds use~ulin the ~ eviation of allergi~ disea~es and there is, in particolar, a
need for therapeutic agents which aPe effective in treating im~ediate
hypersensitivity conditions such as a thma.
We have discovered certain aurone derivatives po~sessing the following
basi~ skeleton, which have such useful ac~ivity.




' 6~$~ ~




According to t~e pres~ntinvention there is provided ~ substituted aurone
o~ formula I




R~ Cll ~6




in which R~ 2, R3, R4, R5 and R6 are the s~lme or different and can each represent
hydrogen. halogen, Cl_~ alkyl, Cl~ alkoxy, C3-8 cyclonlkyl,


30~
--2--

optianally substituted phenyl, Cl_6 halo~l, amido, amino, cyano, hydroxy, nitro~C2~ kenyl, carboxyl, tetra~ol-5-yl or ~ HCOO~; or in which R1 ~nd R~ talcen
together represent ~ group of formula ~I=CH-CEI=CH-; provld~d 'chat at least oneof Rl, R2~ R3~ R4, R5 ~nd R6 is carboxyl, te~a~ol.-5-yl or ~H=CHCOOH, or a
pharmaceuti~ally-acceptable salt or ester thereof.
The compound~ of formula I may ea~ist in the (E)- or (Z)- form, the (Z~-
form being prefer~ed.
A more particular group OI compound3 is one of formul~ ~I) in which R],
R2, R3, R4, R5 and R6 have the values defined above provided that when Rl, R2 and
R3 are all hydrogen at least one of R4, R5 ~nd R6 is tetrazol-5-yl or
-CH-CHCC)OH. It is preferred that the benzofuranone ring be substituted and thus a
preferred group is one of f~mula (I) in which at leRst one of R] ? :R2 and R3 is other
th n hydrogen.
A further particular group of ~ompounds is one oi~ ~ormula ~ n wh~ch
~, R2, ~3, R4, R5 ~nd R~ havQ the values defined above provided that when one ofR], R2 and R3 is carboxyl at least one of R4, R5 And R6 is halogen, C3_8 cyclo~lkyl,
optianally substituted phenyl, C]_6 hal~ mido, cyano, ni~¢o, ~arhoxyl,
tetraz~l-5-yl or -CH=CHCC)OEI. It i~ frequently preferTed that at lea~t one of the
substituents on the free benzene ring is one such substituent and thus a preferred
group is one o~ f~rmul~ (I) in which ~t least one of R4, R5 ~nd ~6 is halo~n, C3 8
cyclo~lkyl, opticnalIy substituted phengl, C]_6 haloalkyl, amido, cyas~o, nitro,carboxyl,te~azol-5~yl or -C H-C H C 0.0 H.




~.-
' :,i

~gr~3o~3
--3~


An espeeially preferred group of compounds is one of formula tI) in whichat least one of R] ~ R2 and R3 is other than hydrogen and at l.east one of R4, R-~ and
R is halogen, C3_8 cycloalkyl3 optionally substituted phenyl, C]_6 haloalkyl, amido,
cyano7 nitro, carboxyl, tetrazol-5-yl or-CH=CECOOH.
The term "halogen" means especially chlorine, bromine and fluorine. The
term 7T Cl_6 a~l" includes, for example, methyl9 ethyl, propyl, isopropyl, butyl, tert
butyl, pentyl and hexyl, being prePerably methyl~ ethyl or tert-butyl. The term "Cl_6
aL'coxy'1 includes, for example~ methoxy, ethoxy, propoxy, buto2y and is preferablv
metho~. The term "C3_8 cycloal~l" is preferably cyclohexyl. The term "optiondlly
substitu~ed phenyl" includes, for example, phenyl optionally substituted with 1 to 3
substituents selected from methyl, methoxy, halogen and nitro.The term "Cl_8
haloalkyl" can be, for example, any of the group~ listed for ITCl_6 alkylT' substituted
with OnQ to three halo atoms such as iluorine or chlorine and 1~ especially
tr~uoromethyl. The term "C2_4 alkenyln i9 preferably Rllyl. It 19 pre~erred thflt

Rl, ~2, R3, R4, ~5 and P~ be s~lected from hydrogen, halogen, Cl_4 alkyl, Cl_4
~Ikoxy, cyclohexyl, trifluoromethyl, N-isopropylcarboxamido, acetarnido,
dimethylamino, hy~oxy, carboxyl, tetrazol-5-yl or -CH=CHCOOH, ~r 11l and R2
together represent -CE=CH~H=CH-.
Other prefe~red compounds falling within the scope of the aurones or^
formula (I) ~re th~e compounds having one or more of the following characteristics:



ta) Rl i9 Cl_~ alkyl such ~s methyl
(b) Rl is Cl_4 alkoxy such as metho3cy
(c) Rl is halogen such as chlorine

O~9


~d) Rlis C3_8 cycloalkylsuch ~s cyclohexyl
!e~ R~lis am~no
(f) Rlis carboxyl
(g) Rlis a 5- or 6- subs~ituent
(h) Rl ~ hydrox91
(i) R2 is hydrogen
(j) R3 ~ hydrogen
~k) R4 is carboxyl
(1) R4 ~ tetrazol-5-yl
(m) R4 ~ -CH=C H C O O~I
(n) R5 i3 hydrogen
(o) R6 is hydrogen
A p~ti~ularly preferred group of compounds is one in which Rl is Cl_4
alcyl~ carbo~ or halogen~ ~2 and R3 are hydrogen, R4 is c~rboxy1 or -C~I~CHCOOEI
and ~l5 ~nd R6 ~re hydrogen. O~ this group, the compounds in which Rl is slky~ or
carboxyl, R2 and R3 are hydrogen, R4 is carboxyl or -CH=CHCOOH and R5 and R~
are hydrogen ~re most preferred.
The compounds OI formul~ 1 can also be in the form OI their
pharmaceutically-acceptable saltg or esters. Such derivatives sre encountered, for
example, when one ~r mcre of the substituents Rl, R2, ~3, R4, R5 and R6 are the
acid funetion, carboxyl or -C~aC~COOH. Suitnble salt~ 1nclude ~or example those
of mineral bases suoh as ah'culi metal hydroxides, especiaIly the potassium or sodium
salts, or aLcaline earth metal hydroxides, especially the calcium s~lts, or o~ organic
bases such as amines. Pre~erred esters are those derived from Cl_4 alkanols, for
example, the methyl, ethyl, propyl, isopropyl, butyl, t-butyl, methoxyethyl or
ethoxyethyl esters.


-5-

Theinvention a~oincludes a methoclofpreparing aurones o~formula(I)
which ~ompr;ses r~.ctin~ a ~nzaldehvde ofform u~a(D~



~HC _ ~ III



:`
with(a)~ benzofuranone of~ormulatIV)
!~


R2 ~ IV

R~


or(b) ~n~ubstituted ~cetophenone offormulatV~


R2 ~C~2~( V




in which X ~ a lea~ng group;optiona~y fo~owed when ~ne or more o~ Rl, R2~ ~3,
R4, R5 or R6 ~ cyano by re~tiQn ~ith en Qæide to give the corresponding
tetrazol-5-yl compound; and where desired, forming a pharmaceutically
accepkable salt or ester of the c~mpound of formula (I) so prepared.

P~`30~

--6--

As indicated above9 aurones of formula (~ may be prepared by
conden$ing an al~propriatelv sul~stituted benzal~ehvde ~m~ w7th a ben~ofuranone
derivative (IV) as schematically depicted below:



RZ~> ~ OHC

(IV)


(I)

~ uit~blo solvents ~or thi~ r~nction inalude ethero~l ~olvents su¢h a~
dloxRn ~nd te~rahydrofuran and l~quid Qlkanols suoh a~ ethanol. ln general,
temperature is not critical and is only determin~tive ~ the reaction rate. The
reaction wDl proceed a~ all temperatures between ambient and the re~lux
temperature of the reacffon mixture, ~or example, between 25 and 15ûC. The
reaction is pre~erably acid or base c~talysed. Suitable acid catalysts include mineral
acids such a~ hydrochloric acid &nd strong organic acids such as p-toluene sulphonic
acids, whereas suit~ble inorganic or org~nic base catalysts include alkalies such ~s
caustic soda, c~ustic pot~sh, sodium carbonate or triethylamine. This type of
conder~7~tion reaction is well known and those slcilled fn the art will well appreciate
the n~ture o~ the reaction conditions And reagents necessary to produce a particular
aurone of formula (I~,

3V~


An alte~native process for preparing compounds of formul~ (I) involves
the reaction of anh~suhst~tuted acetophenonet~` with an appropriate benz~dehyde
(m) as depicted schematically belowo
R1 o R4




R2 _~ + OHC ~RR~;

R (V) ~ (III)
-7

(I)

where X is a leaving group, such a~ i'or example h~log~2, e9pecial1y chloride orbromide, or the tosyl group. Suitable 901vent9 Include ethereal Yolvents such asdioxu~ and tetrahydrofuran and llq~d alkanols such as ethanol. ln this instance the
re~tion is preferably base catalysed using a catalyst such as caustic soda, caustic
p~tash or sodium car~onate. Temperatures from 0 to 15aC c~n be u3ed to e~ect
the re~ction. The reactant~; oi~ formula (m), (IV) and (V) are in the main known~ompounds and can be prep~red by well cnown routes described in the literature.
~ ad~ition, compounds OI formulA (I) in which one oi~ the R groups i9
tetrazol~5-yl can be derivecl by preparing the corresponding nitrile and forming the
tetrazole therefrom utili.Ying a preferably non-nucleophilic azide, eor example
trimethylsilyl azide, in ~ high boiling solvent such as dimethylformamide at
temperatures sb~ve 10~C.

w8 ~

These re~ctions ~vi31 produce the (Z)- 1somer which, if desired, can be
conve~te~ to the co~respo~ding l~isomer b~ phct.-~!yffc m~t1~s wh;~.~h are ~e?l
h~n ~ the art.
The aurones of ioPmul~ (I) have ~een ~hown to be useI7l1 in the
prophylacti~ treatment of asthma in mammals. I~ ctivity has been demonstrated
in guinea pigs using either the "Herxheimel~" test descPibed in the Journal of
}Ig~l~v ~L~L;L~ 2Sl 9S2) or the "guine~-pig ~hopped lung test" described
by Mo~gar and Schild in the Jourllal OI Phy~ ~London) ~ 3], 207 (1956) or
Brocklehurst Journa of Ph~iolo~ (London) ~52, 414 (1960). Compounds are also
ective in the "rat p~ritoneal anaphylaxis tes~" based on an allergic re~ction in the
peritoneal cavity of the rat, ~9 degcribed by Orange, Stechschulte and Austen in~ed.Proc. 2~ 1~10 ( I ~û9).
The "Her~h~ime~" test i~ bQsed on an ~Jlergic broncha~pasm induced in
gulne~ pigs which closely re~emble~ an asthmatic attack in m~ medi~tors
causing the bronchosp~sm are very similar to tho e releAsed when sens~tised human
11mg tissue is challenged with ~n antigen. Compounds of the invention h~ve
e~hibited a~ff~rib in the ~Her~heimer" test at dosages ranging irom 2~ mg/kg to 200
mglkg.
Th2 compo~ds of fo~mul~ (I) may be ~dministered by v~ious route3 ~nd
~or thi~ purpose mQ~T be l~ormulQte~ in ~ v~riety Oe ~orrn~, although it is Q spe~i~
feQture o~ the compounds oi~ th~ invention that they are effective when administered
orally. Thus the compounds OI the invent~on may be administerecl by the oral andrectal routes, topically, pflrenternlly, e.g. by inje~tion, in the form of, for example,
t~blets, lozenges, sub-1ingu~l tablets, sachets, cachets, eli2Qrs, suspen~ions, aerosols,
ointments, faP example, containing up to 1096 by weight o~ the aetive compound in a
suitable base~ soft ~nd h~r~ gelatin c~psules,

'~,'

.3~)g
_9_
suppositories, injectian solutions and suspellsions in physiologically acceptable
m~ia, an~ st~rile packeg~l po~ud~!s adsorh~ onto ~ sv~pot~t matePial fOl' ~e~
injection solutions. The nature of the various excipie~ts and aclditives required to
produce such formulations will be well-l~nown to those skilled in the art.
llowever, some examples of excipients which may be employed in the
pharmaceutical formulati~ns of the present invention are lactose, dextrose, sucrose,
sorbitol, msnnitol, propyIene gly~ol, ~iquid p~raIfin~ white soft para:Efin, kaolin,
~umed silicon dioxide, microcrystalline cellulose, calcium silicate, silica,
polyvinylpyrrolidone, cetostearyl alcohol, starch, modified starches, gum a~acia,
calcium phosphate, cocoa butter, ethoxylated esters, oil OI theobronna, arachis oil,
alginQtes, tragacanth, gelatîn, syrup lB.P., methyl cellulose, polyoxyethylene sorbitan
monolaurate, ethyl lactate, methyl and propyl hydroxyben~oate, sorbit~ trioleate,
sorbit~n sesquioleate and oleyl alcohol and propellants ~u~h as
trichlommono~luorometh8ne, dichlorodiiluoromethane and
dlchlorote~ra~luoroethane. In the ca~e oi~ tabletY, a lubricant may be incorporated to
prevent sticking and bindln~ of the powdered ingredlents in the dies nnd on the p-mch
oi~ the tabletting machine. For such purpose there may be ernployed Por instancealuminium, mQgnesium or calcium stearates, talc or mineral o~l.
The invention also include~ a ph~rmaceuticsl i~ormulation which
comp~ises as an active ingredient a compound OI formul~ (I) or a
pharmaceutically-ac~eptable s~lt or ester thereoL77 associated with a
pharmaceutic~lly-a¢ceptable carrier therel70r~ Pharmaceutical formulations can be
provided in dosage unit foPm, each dosage unit preferably




~,

o~ ~

-10--

containing from 5 to 500 mg. (from 5.0 to 50 mg. in the case of parenteral
~dmin-stration, from 5.0 to sn n!~. ~n the case o~ r~alat;on anc~ f~om ~ to ~OQ mg.
in the case of oral or rectal administration) o~ a compound of formula (1). The term
"unit dosage form", as used in the spe~ification and cIaims, refers to physi~ally
dis~rete units suitable as unit~ry dosages for hwnan subjects and animals, each unit
containing a predetermined quantity of acffve material calculated to produce thedesired therapeutic effect in association with the required pharmaceutical diluent,
ca~Tier or vehicle.
Dosages of from 0.5 to 200 mg/kg per day, preferably 1 to 20 mg/kg of
active ingredient may be administered, although it will, of course, be understood
that the ~mount of the aurone OI ~ormula ~1~ actually administered will be
determined by a physician, in the light of the relevant circum~t~nces incIuding the
condltial to be treateci, the ohoice o~ compound to be administered and the cho~en
o~ route o~ adminlstration and therefore the above preferrecl dosage range is not
intended to limit the scope of the present invention in any way.
The ~ollowing 33xamples illustrate the invention.

EgAMPLE ]
(Z)~'-C~rbox~1-2-benzyliden~5-methylbenzofuran-3(2H~-one
~J~hloro-2-hydroxy-5-methylacetophenone t8.73g,û.05 mole)rChem.Ber 41,
4271,(1908)] and 4-carboxybenzaldehyde (7.S~, 0.05 mole) were dis~olved in ethanol
(100 ml) and tha mixture heated to 60C. Sodium hydroxide (4g, 0.1 mole) in w~ter
(20 ml) was then slowly added to the stirred mi~ture which turned deep red. After I
hour at 60C a pale yellow precipitate formed which was then reflu2~ed for a further
hour.

~PZ.3V5~


The suspensicn so formed was then cooled to 0C and acidified with hydrochloric
acid ~5n~. The result~nt psle ye11Ow solicl was filtered o~, wasllecl with water, ~ie~'
unde~ reduced pressure ~nd recrystallised from dioxan to yield the title compound ~s
pale yellow nee;lle~, m.p. 288-290C(decomp.
EXAMPLES 2 TO 5
The following eompo~d3 were similarly prep~red u~ing the appropriate
benz~ldehyde ~nd chloroacetophenone.
(Z)-2'~arboxyl-a~enzyliden~S-methylbenzofur~n-3(2H)~ne
m.p. 187~C.
(Z)-2'~C~rboxyl-2-benzylidene-6-methylbenzofuran-3(2H)-one,
m~p. lg6-198C. (de~omp.)
(Z)-2'{~rbo~ a- benzylidenenaphtho (2, l-b) ~uran-3 (2H) ~ne,
m.p. 207-208C.
(Z)~'-<;'flrboxyl-2-be~zylidene-5-isopropylb~nzo~ 3~2}~)-one,
m.p. 262-ZB3C.
BXAMPLE 6
(Z)-3-C~1-2~enzylidene-5-metho~ybenzofuran-~(2H)-one
5-Metho2cybenzofuran-3(2~)-one (6.0g, 0.036 mole) ~Ann en ~ 281, n914)] ~nd
3~carboxyb~zQldehydQ (5.4g, 0.036 mole) ~J.Chem 8OC. 4778 (1952)1 were dissolvedin dio~an (50 ml) ~nd concentrated hydrochloric acid (10 ml) added. The resultant
yellow solutian was then heated under re~ fcr 2 hours. On cooling Md addition ofwater (20 ml) a yellow precipitate formed. Thi9 materiRl on recrystallization from
acetic acid ylelded the title compound as yellow needles, m.p. 252-254C.




.~
s

1 2

}-_LEB 7 O 3 6
The followin~ cs>rnpo~ds were prepare~ u~;r~ a Dl~ocess simil~r to that o~ m~e
vYith appropriate v~riation QI the berlzofuranDne and benz~ldehyde.
(Z)-2'-~arboxyl-2~e~lzylidene 6-methoxyb~zofur~n-3(2EI) one,
m.p. 217-220C (decomp.)
(Z~-3'~bo~ 2-benzylidene~6-metho~be~azofilr~n 3(2El)-one,
m.p. 258~60C [de~or~lp~)
C~rbo~1-2~enzyliderl~6~ etho~ybenzofuran-3(2H)~rle~
m~p. 273-275C (decomp.3
(Z)-3~-Carbo~yl-2-benzylidene-5~methylbe~lzofuPan-3(2~)-one~
m.p. 264-265C.
(Z)-3'-C~rboxy1-2 benxylidene 6-m~thylbenzofur~n-312H)-o~e~
m~p~ 283 2~i4Co
(Z)~/-Carbos~rl-2-b enzylidene-6-methylbenzo~uran-3(2~ one9
m.p. 288-~8gC.
(Z)-3'-C~bo~l~'~ydroxy-~-ben~:lidene-6-methylbenzoIuran~3(2H)~one
m.pD 290~291C.
~Z)-3'-Carbo~yl~'-hydro~:y-2-benz5tlidenebel1zofuran-3(21I)-one,
m.p. 268-270C.
(2;)~'~C~rbo~yl-2~en~ylidenebenzofuran-3(2H)-one,
m.p. 274-275C
(Z)-3'-CQrbog~ be;lzylidene-6~~ oben~ofllran-3(2~ one,
m.p. 278-280C.
(Z)-2'~arb~ 2-benzylidene-~hlorobenzofuran-3t2~I)~e,
m~p. 20S-206C.
(Z)-3'-C~rbo~rl-2~zyl1dene-6 chlo~obel~ofuran-3~2H)~ne,
m~p. 286-288C~ ~
(Z)-4'-Car~xyl-2~nzylidene~5~hloroben~o~ 3(2~ one,
m.pO.~ 300C.

~.~9~?;~
~13-


tZ)-3'~rbo~ 2~nzyliden~-5~ethylb~zofuran--3(2H)~ne9
rn.~. ~5?C.
(Z~-3'~arboxyl-2 benzy:lideneben~of~n~3(2F~)~ne9
m.p. 259-26DC.
(Z)-4'~[(E)-C~rbo~yvinyl]~ nzylidene-5-methylb~z~ 3(20 one,
m.p~, 2~5~276C.
(~;)-3'~arbo~ 2 b~zylidene-5~y~1~he2~ylbenzo:furan-3(2EI)~ne7
rn~pO 252-253C~
~Z)~ Carboxyl-2-benzylidene-& chlorobeDzoîuFan-3~2H)-one,
m.p.~ 300C.
(Z) 2'-C~rboxyl-2~en~1idene-6-~hlorobenzoIuran-3(2~I)~ne7
m.p. 1~4C.
(Z)-4'{(E3-2-C~boxyvinyl]-2-ben~yliderl~-6-hyclroxyb~llzoPuran 3(2H~-on~,
m.p.~300C (de~omp.)
) 3'~nrbo~1-~-ben~ 3en~6 hydroxybenzDfurun-3~2~ ne~
m.p. 323C (decomp.)
(Z)-2'~rboxyl 2-be~ ides~ hyd~xsrbenzofur~n-3(2H~ne,
m.p. 282-283C.
(Z)~-[(E)-2~arbo:~vinyl~-2~enzyli~ene-5,7~iehlorobenzofuPan 3(2~ on~,
m.pO~ 300C.
t~)-3'~(E)-2~ rbo~;yvinyl]-2~erl~ylidene 5,7~i~hlorobenzo:~ur~ 2~)ffne
m.p. 300C
t~ 3'~(E~2 C:~Lrboxyvlnyll-2 benzylldene~-hydwxyben~o~urQn-3~2H)~ne,
m.p.~30ûC
(Z)-3'~(ie)-2~arboxyvinyl~ -2~enzylidene~5-metho:~b~zo~urall-3-(2H~ne~
m.p~ 242co
(Z)-3'~Qrboxyl-2~en~ylldenenaptho(1,2~)furan-3(21~)~ne9
n~.p. 276-278C.


14~


(Z3-3'-r~E~-2~arboxyvinyl)] -2-benzylidenenaphtho~1,2-b)furan-3(2H)~ne7
m.p. ~n~.
~Z)-3'~arbo~yl-2-benzylidene-4~ydroxybenzofur~)-3(2H3~ne7
m.p~285-287C.
(Z)-2'-Carboxyl-2-berizylidene-5,7~ibrom~4-hydroxybenzofuran-3(2H)~ne,
m.p~258-260~



E2~A~aPLE 37
_____

4{~y~nobenzaldehyde (13.1g, 01 mole), ethylesle glycol (6.2g 0.1 mole) and toluene
-4~ulphonic acid (19.0 mg, 0.1 m. mole) were refluxed in benzene ~la0 ml~ for 8 hours
using ~ Dean and Stsrk apparatus. I'he b~nzene was then evaporated to dryness to
give 4 cyano-(2-1,3 dioxaldne) benz~ne ~Q9 a W~l~y colourless solid (m.p. 44~5C~
which wa~ u9etl without ~rther puri:~ication4
The above dioxalane (lY.l~, 0.1 mole), sodlum azide (fi.5g, 0.1 mole) and
lithium chloride (~.5g, 0.15 mole) were refluxed in 2-met~oxyeth~nol (100 ml) for 8
hours. The suspensiall was then poured into ice and hydrochlori~ a~id (5M). On
standing, this solution deposited white crystals of 4~5-tetrazolyl)-benzaldhyde, mOp.
~OOC.
Ihi~ benzaldhyde and 5~hlorobenzofuran -3(2E:I)-one[AIulalen 2924 405
34~] were reacted togethel~ using ~he procedure o~ Example 6 to yield the title
compound which was recrystallised from dlmethylformamide, m.p. 260C (decomp!.


!



-15

~AMPLE~_38 T0 4~
~e ~ol7owing comp~7f's ~el e sim~ y prepared using the a~ropr ~te
cyanob~nzaldehyde a~d benzofuranone.
(Z)-3'~5 Tetr~zolyl)~2~benzylidene-5-methoxyben~ofur~n-3(2}I~ e,

m.p. 278-280C (decomp.)
~Z)-4t-(5-Te~azolyl)-2-benzylidene-6 hy~oxybenzl3~uran-3(2H)~ne,
m.p. 300~ (decomp~)
(Z)-4'~5-Tetrazolyl)-2~enzylidene-5-methoxyb~a:o~uran-3~H)~ e,
m.p. 268-270C (de~mp.)
(Z)-3r~5-Tetraz~lyl)-2~e~zylidene-5,7 dichlorobenzoiuran-3(2~)-one,
m.p~ 283-285C ~decomp)

E~AMPLE 42
. . _
~Tetr~z~.v~ne-5-eth~rl:~n 3(2H)-one
5-Ethylbenzo~ur~n-3(2H)~ne (3.4g, 0~02 mole) rJ. Indinn Chem.So~ 20 (19B5)1
~nd 3-cyanoberlzaldehyde (2.~2g, 0.02 mole) were dissolved in dioxan (lO0 ml) and
concentrated hydPo~ ric acid (5 ml) added. The result~nt yellow solution w~s
heQted un~er refl~ i~or 2 hours. t)n cooling, yellow needles oP
cy~o-2-b~n~ylidenebenzo:t`ur1n-3(2EI)~ne mOp. 162C ~rmed ~nd were
r~moved by ~iltration. The aurone (0.5g, 0.0018 mole) ~nd trim~thyl silyl azide (l~,
0.086 mole) were rePluxed together in dimethyl~ormamid~ for B hvurs. The cooled
qolution w~s poured into lce ond hydrochloric a~id. The suspension WR~ then heated
to 70C ~or 30 minutes ~d after coolin~ the precipitate Wa9 ~iltered o~. ~his
ye11Ow oily solid, rl~ter chromatogr~phy, yielded the title compound, m.p. 242-243C.


~ 160

E:gAMPLE 43
____
~Z~-2'-~arbo~n~2-~enzv7iden~5~arbomethogv~-aminobenzofuran-3~?F!`~ne
The methyl 3 acetyl~-hydro~y-6~minobenzo~Lte ~8.0g, 0.038 mole~ in
diehlo~ometh~e (250 mlj was added to trifluoroaeeti~ anhydride (16g, U.076 mole?and the solution stirred at room temperature of 15 minutes. On evElporation, thepale yellow solutian y~elded methyl 3-acetyl-
4-aceto~y 6-~iflu~roa~etamidobenzoate, m.p. 130-131Co
CoppeP (Il)bromide (17~0gg DoO76 mole) was suspended in ethyl acetate
(300 ml) by rapid stir~ing. To this suspension wss added the benzoate produ~ed
above (11.5 g, 0.038 mole) as a solution in ethyl acetate (200 ml) and the result~nt
mi~ture was stirred and heated under relux ~or 3 hours. The pale gre~n ~uprous
bromi~ so formed was removed, after coolLng, by filtration and the ~;olution
evAporated to eiv~ a pale yellow sol~d whi~h wa~ re~ryst~.llised from
ether/petroleurn ett~r (4ll-60C) yielding methyl
3-bromoac~etyl-4-acetoxy-6~tri~1uoro~cetamiàobenzoate as white c~ystals,
m .p260-:161C3
This compolmd (1.9g,0 0û5 mole) and 2~carboxybenzaldehyde (0.75g, .005
mole) in metltanol ~100 ml) were then heated to 60C. Sodium hydroxide (0.6~, 00015
m ole) un water (20 ml) was slowly added to the stirred solution. The resllltant red
solution w~s he~ted u~der re~uLY for 3 hour3 nnd then poured on to ice ancl
hyclro~hlnric acid (5~j. The ye~ow solid 90 form ed wns ~iltered o~ and dissolved in
aqueous sodium bi~rbone~te soluti~n (10%) at 50C. The pll OI this solution was
adjusted to 7 ~n~ ~mberlite Res~n DRA-401111 the hydro~yl fOrM added. The res~n
w~s then ~lltered o~f and washed, ;~ilstly with wate~ and then with glacial acetic
~cid. On ~oncentraffon the aceti~ a~id washings yieIded the title compound &s
bright yellow prisms, m.p. 280C (de~omp.)




* Trademark

~17
EgA~PLE 44
~Z~-3'~arbox~1-2~enzvlidene-5 7~ihromo~lvc~o~rbenæofur~-~?~'-one
Finely ground ~opper ~ bPomisle (88g9 0.4: mole3 w~s suspeslded in a 50 sa mixture of
ethyl ace~ate and ~hloroform (200 ml~. 296-Dihydro~y~cetophellone (lOg, 0.0657
mole~ in chloroform (20 ml) was add~ to the abovle suspeDsi~n whi~h w~s stirred
mlder re~l~g fcP 8 hou~, hyd~g~ bromide being e~olv~d~ Afte~ cool~ng the ~opp~
(I~ bromide formled in the above rea~ff~n w~s ~iltered of~ and the so1ution evaporated
to dryn~ss to give 3,5-dibroms~2,6-dihydro~_~brs)moa~etophenone, m p. 150C.
The6~romoacetophenone ~3.2g, U.21 mole) and s~ium Qcetate (20 g~ were re~luxed
in 90% eth~nol (100 ml) f~ 15 minutes~ On cooling and following the additi~ o
w~ter (100 ml), the yellow solution deposited a greenisl1 solid which ~ras
recrystallised irom ethQnol/water to glYe
5,7~ibrom~4 hydroxyb~zo~urQn-3~2H)-one? m.p~ 185~C (decomp.~
The benzo~uran-3(2H)-one wa~ then reac~ed with 3-~arboxylbenzaldehyde
using ~he procedur~ des~rlbed in :Elc~mpl~ ~ to ylel~ the title compound, m.p.~300C

(decompO)
EgAMPLES 45 AND 46
The ~ollowing aompo~ds were prepared by fl m~hod simil~r ~o E2~ample 44 using the
appropriate benzaldehyde.
~Z) 4'-C~rbos:yl-2-benzyli~ene-5,7-~3ibrom~4~hydro~benzo~uran--3(2:~ne, m~p.
300~C.(de~omp)
(~)-2'CRrboxyl~2-benzylidene-5,7~1ibromo 4~ydroxybellzofutan-3~2~ne,
m.p. 258-26~C
E:~AMPLE 47
(Z)~ (E)-2~arbox~rinyl1-2~enzyliderle-6-amino-5~yanob~zofuran-3(2
one

.`3~)~

~18-


4~ 5~yQno-2~droxyacetophenone (3.C.S.P~k~ I 1979 3 677~ ~s cor~v~Pted
i~to .~t~luo~o~eetami~5~r~v-2~yd~1~ tophenone~m~p- ~14~C) IlSing the
pro~edure de~cribed ila ~ample 43.
This ace~oph~orle was then brominat~d lE;ing ~p~er ~3I) bromid~ b~ the
method desc~ibed in E~ample 44 to yield 4~ 1uol~cetamido~yano-2~ydro~y-
~romo~cetophenone m.p. 202~C,
The~romoacetophenone (3.8g 0.011 mole~ w~s dissolved in eth~nol 50 ml
~nd e:~cess sodium acet~te (lOg) added ~g with w~ter (10 mI). The m~ture was
~en re1u~ed fcr 23 minutes md Q~2 cooling depo~ited ~n ~rRnge solid whidl was
recrysWli~ed from e~han~ water to yield orange p~tes o~
6~mi~5 cganobenzofuran-3(2~one,
m.p. ~70C ~decomp)
This ben20:1uranon~ w~s ~en re~cte~ with (E) 4-~rmylcintlarllic a~id
u~ing the proce~ur~ cribed in P~EImple 6~ the title compolmd being obtAined Q8
oranKe cry3t~s, m.p.9 3000C.
MPLE: 48
ycl~ ~
4-Cyclohe~ulphenol ~8~g, ~,5 md~ d a~ l chloride (39g, O.S mol~)
were heated togeth~r at 170C for 3 hou~s. The cle~r liq~d ~o ~ormed WQ~ then
~oled to 100C. and ~luminium c~l~rlde (133g, l.Omole) 1dded ~lowly, '~e brown
st~cky o;l wn~ then he~ted to 130~C f~ 5 ho~ . A~ter cooling, ice and hydrochloric
acid ~re added and the phenol e~tracted w~th chloroitorDI. llus e:~ract w~s thRnetr~porlted to dryness snd tl~ residue ste~m dist~lled to give
2~cety1~ cydohe~lphenol as a cle~r oiL Th~s phenoI was then re!QCte~5 ~ith
copper (II) bromid~ u~ng ~ p~cedw deseribed in E~ample 43. Thi$ reacffan
~ielding ~rorn~acet~ clohexylphenol ~s ~ ye~low o~ This On ~æ ~issolv~d Ln
eth~nol noo ml~, snd sodium aceeate ~44g) nnd ~ter ~20 ml~ added.

3 ~3 ~
-19~


This solution was the~ reflu~ed for 10 milrlUlteS7 cooled ~nd wat~ adde~ to deposit a
hroYIm oil ~hich waS e~trac~ed wit,'l chlo~oform. On evaporation to ~ryness the
chloro~orm 2xtract yi~lded the S~yclohe~ylbenzof.urQn 3(2~ne ~hich was then

re~et~d with 3-carboxybenzaldehyde using the procedure of EXample 6 to yield the
title comE~ound as ye11Ow cryst~ls, rn.p. 252-253C~
E~EAMPLE 49



(a) Methyl~-Qceto~ybenæoate (126g, 0.65 rnole~ and alwninium chloride
(220g, L63 mole) were intim~tely rnixed, stilred and reacted ~t 16ûC by the method
o~ G. l:~ora et al., ~ur.J. Med.Chem 1978 ~ 33. The crude solid procluct obtained
afte~ ~cid keQtment WQS stirred with saturated sodium bicnrbon~te soluticn an~ the
mixture filtered. Tha :~iltrnte WR9 cnrei~lty acidi~ied to give
3-~cetyl~hydroxy~ oic ~id~ which wa~ ~ltered o~, water wa~hed ant1 dried,
m.p. 232C.
The Insoluble solicl ~rom the above bicarbonRte e~traction was dissolved
in dilute ~odium hydroxide (2N) solution an~ careiully acidi~ied with dilute
hydrochl~ic ncid ~5M~ solution to give methyî 3^~cetyl~-hydroxyben~oate, which
n~ter filtratiorll water washing and drying, had m.p. 90 92C.
(b) 3-Acetyl~ hydroxyben~oic acid (24.0g. 0.133 mole) wns di~solved in
dioxane (400 ml) at ~0C ~d bromine (7.2 ml, 014 mole) aclded ~opwise with
stirring. Tha colour soon ~ded and ~lter 45 minutes the cle~r supernatQnt was
dec~nted ~rom some insoluble m~erinl and evnporQted to give Q llght straw coloured
solid~ 3~romoQc2tyl 4-hyclroxyben2.oic ~cid, m~p. 226C7




?~
`~..} ?



20~

(c) The product from (b) was dissolved in ethanol/water (35~/70 ml\, sodium
acetate '30g' added and the solution stirred at 60t~ for '0 minutes. 'rhe deep orange
red solution was cooled to 10C, stirred, and carefu31y acidified with 5N hydroehloric
acid solution. The resultant bright yellow solution was diluted with an equal volume
of w~ter ~nd storecl in a refrigerat~r overnight~ The yellow crystal~ine solid was
filtered o~, washed with cold water and dried to give
5~arboxybenzofuran-3~2H)one, with m.p. 204C (decomp.)
(d) 5-Carbo2~ybenzofuran-3~2H)one(3.56g., 0.02 mole) and 3,4,5-trimetho~
benzaldehyde (3.92g., 0.02 mole) were d:issolved in warm dio~Ane (50 ml.),
concentrated hydrochloric acid (10 ml) added and the mixture stirred and gently
heated in a steam bath for 15 minutes. After cooling and the additiMI of an equal
volume OI water the yellow crystalline solid was filtered ofi, washed with water and
driedJ Recryatal1isation from glacial acetic ~cid gQVe~ th2 t~tle compound, m.p.
290C.
qP:LES 50 TO 60
The following compounds were prepared by a method similar to that
described in Example 49:
(Z)-2-Ben~ylidene 5~arbox:ybenzo:~uran-3~2H)one7
m.p. 280C.
(Z) 4' Chloro-2~enzylidine~5~arbo~{gbenzoIuran-3~2H)one,
m .p.~ 300C.

(Z)-2' Chloro-4'~imethylamino-2-be~rlzylidine~5-carboxybenzo.~urall-3~2H)one.
m.p. 275C (decomp)
(Z~-4'~13utyl-2-bellzylidene-5~arboacybenzo:Fursn-3~ 2H)one,
m.p. 252C.
(Z)-~'-Dim ethylamino-2~enzylidene-S~arboxybenzofurall-3~2El~on~,
m.pO 295C.

-21 ~

(Z~-4'-Methoxy-2-benzylldene~carboxybenzofuran-3~2H)one,
m.p~300C.
(Z~-4'-[~E~2~arboxyvinyll-2-benzylidene~5 carbo.xybenzofulan3~2H~one,
m~p.>300C~
(Z)-3'-C~rbo~yl~'-hydroxy-2~enzylidene-5~arboxybenzofuran-3~2H~one9
m.p.~ 300C.

(Z)-4'-Acet~mido-2-ben ~rlidene-5 ~ arbo2~ybenzoIuran-3~2~I)ones
m.p.~ 300C
(Z)-3'-Trinuorom e~hyl-2-ben~ylidene-S~arbo~ybe~zofuran-3~2H)one,
m.p. 264C.
(Z)-3'-(N-Isopropylcarboxamido)-2~enzylidene-5-cQrboxy benzofuran 3-(2H)one,
m.p. 300C.
EXAMPLE 61

5-( ~!~Y~I~n -
~(~ 5-Acetyl-2,4-dlmetho2~yben~oic acid (Ber. 41~ lffO7, 1908~ (21.1g, 0.094
mole) was stirPed in dioxane (200 ml.) at room temperature and brornine (5 ml., ca
0.1 mole) was added dropwise. The brornine colour gradu~ly disappeared o~er 30
minutes and tlle mixture WAS then gently w~rmed in a steambath for 30 minutes,
cooled ~nd the dioxane removed in vacuo. The solid product was treated with boiling
__ _
ethyl acetate, ~iltered hot and the ~gltr~te evaporate{l to gi~e
5-bromo~cetyl-2~-dimethoxyben:~oic acid, m.p. 236C.
(b) The product from (a) (21.6g., 0.0~1 mole) W19 stirred in dichloromethane
(~50 ml), eooled In M~ ice ba~h and boron tribrornide (25 ml) added dropwise. The
solution was the~ heated under reflux (water bath) for 4 hours. The mixture was
cooled and poured onto ice tl kg.3. After removal OI dichlorometllane, the result~nt
pinlc solid was filtered off, wRter washed, sucked dr~ ~nd dissolved in ethaT201/water

no/~o 11~

31`3'~3
-2~-

Sodium acetate t25g) was added and the solution warmed at 6~S~ for 30 minutes.
A~ter coolin~ and the removal of etb~nol in ~ ~urthf~ t~ 5
~dded. The solution was cooled iJI an ice bath ~nd hydrochloric acid solution r5~)
added dropwise with stirring to pH2. After overni~ht storage in a refrigeratur the
pale yellow crystalline solid was filtered o~, vv~ter washed and dried to give the
title benzofuranone9 m.pn 216C.
EXAMPLE 62
(Z)-3'~~b~8g~1-S~ydro~7b n2:ofuran-3~.H~one
5-carbo~-6-hydroxyben2oIuran-3-t2H)one (5.82g9 0.03 mole) wa~ dissolved in
dio~ane (75 ml~, 3-carboxybenzaldehyde t4.50gO, 0.03 mole) added, followed by
concentrated hydrochloric ~cid ~15 ml). The soluti~n was gently hented on a steam
bath fo~ 30 minutes with occasion~l stirring. '~le solid mixture was cooled, diluted
with ~n equal volume of water and stored in a refrigerator ~or 1 hour. The product
was fllt~red of~ water wn~hed nnd dried~ ~lecl~tallisation ~rorn
dimethylPormamide gave the de~ired compouncl with m.p. 335C (decomp).
EgAMPLE5 63 AND 64
The fo~lowing compounds were prep~red by a simil~r method to that describe~ in
Example 62.
(Z~ 3'-Carbo~ hydroxy-2-benzylidene-5~Qrboxyl-6-hydrOxy
ben~.ofuran-3~2H~one,
m.p. 332C (decomp.~
(Z)-4'~Te~razol-5-yl)-~-benzylidene-S-cQrboxyl-6-hydro2~y benzo~uran-3-~2H)one.
m.p. 3~7-28C (decomp.~


-23


E:~AMPLE 65



Methyl-3-acetyl-4-hydroxy benzoate (5.39g 0.028 mole~ was stirred in dioxan (200
ml~ at ~0C and bromine (1.5 ml~ adc3ed drops~liseO After 45 minute~ the colourless
solution was evaporated to g~ve a straw coloured oil which was dissolved in
ethanol/wateP (75/15 ml.). ~odium acetate (6.0g) was added and the solution stirred
at room temperature for 5 rninutesO The red solul:ion was poured on to ice ~lOOg) and
extracted via chloroform. Evaporation of the chloroform extract gave
5-methoxycarbonylbenzoîuran-3~2H) one as an orange red oil( 659~ pure by ~MR).
ThLs product was imrnediately dissolved in dioxane (50 ml.~, ~
3-carboxybenzaldehyde (4.5g., O.û3 mole) added, followed by concentrated
hydro~hloric acid (10 ml) and the solution heated on a steam bath for 15 minutes.
Worlc up wa~ as Example 49 with recry~talllsRtion ~rom dimethyl~orrnnmide to give
tha desired aur~ne~ m.p. 281)C.
E~AMPLE 61i



(a) 3-Aminophenol (54.5g., O.S mole) and acetic anhydride (200 ml) were
stirred and heated on a steam bath ~or 2 hoursO The straw coloured liquid was
ev~pol~Qted in vacuo to give a vLscous oil which was heated to 110-120C aluminium
chloride ~170g. 1~27 mole) being added gradually with stirring. A~ter 30 minutes the
solid product was cooled somewhat and care~ully decomposecl with ice/water ~CR
SOOg.) ~ol1owed by concentr~Lted hydrochloric ncid (200 ml.), stirred well nnd wQrmed
slightly on steam bath. On cooling, the crystalline solid was filtered off, water
washed and dried to give the clesired compound 2-hyclroxy-4-acetamidoacetophenone,
m.p. ] 40C.


2 ~


(b) The product :erom (a) (14.0g û.072 mole) was dissolvecl in ethyl acetate
~300 ml! and added to a stirred suspension of eo~per~` bromide/32g. 0.1~ m ole`;n
ethyl acetate (lOO m ole). The mixture was heated under re~ux for 4 hours,then
Pilterecl hot ~nd the ~trate evaporated in vacuo to give an oil which crysta~ised.
This solid was converted to the ben~ofuranone ~d reacted with
3-cQrboxybenzaldehyde (as ~cample ~5~. :EIowever, during this reaction the product
was partia~y d~acylated and it was urther reQcted with acetic ~nhydride (20 ml)
under re~ux to c~nvert to the f ~ y acehy1ated compoundO This reaction mixtura
was poured onto i~e (10~ g~ and the e~cess acetic anhydride hydrolysed. The
resultant solid was filtered off and recrystallised from glacial acetic acid/water
(50% v/v) to give (Z3 3'~arboxyl-~enzylidene-6-acetalllidobenzofuran-3~2H~one,
m.p. 31D5C (decomp.!
EX~MPLE 67

. .
( Z;)~'-Chloro-2-benz~dene-5-n bu ox~arbon~l bel~ofuran-3-(2~I)one
Z~'~hloro-2~enzyliden~5~arboxybenzo~uran-3-(2:EI)olle (3.0g. 0.01 mole) wa~
suspended in n-butanol (5a ml), concentrated sulphuric acid (1.5 rnl) added dropwise
with sffrring and the mixture heated ImdeP re:flux for 5 hours. The resultant ye110w
soluffon on c~ling deposited yellolN ~lu:i~y needle crystals OI the desired n~utyl
este~. The cryst~ls were f~tered of~, washed with cold n-butanol, then diethylether
~d dried, m.p. l54C.
EXAMLE 68
(E)~'-Chlo~ benzo;Furan 3~2~I)one
(Z)-4~ hlor~2~enzylidene-5-n-butoxycarbonyll:~enzofuran 3~2H)one ~l.Og~ ~was
dissolved in b~zene (800 ml) and irradi~ted in a 1 litre Hanovia photo~hemi~al
reactor for 15 hours. The solution was e~aporated in vaeuo to give l.~g of solid with
m.p. ca 13D and having an E/Z isomer ratio of r5/25 (based on NMR and H.PLC3.


~ ~5--

" ,. *
500 mg o:~ this solid wa~ chroma~graphed on a Sor~sil silicQ gel colwnn
!?OOg.~ using be~zene ~s the developing svlvent and the fractions containing the
faster moving (E)-isorner collected. These fractions were buLked and evaporated to
give a yellow cry~ta~ine solid; yield 35~ mg. o~ mp 142C and having an E/Z isomer
raltio of 88tl2~
200 mg. this solid w~ recrystallised from dichloromethanet40~0C
petroleum ether (lt3 ~/v) to give 130 mg. of ~rystalline solid o~ m.p. 142C and
l~virlg an ~/2; isorlle~ raffo oP ga.~/7.5.
The ~ollowing foE mulati~s were prepared using as A~tiVe ingredient the
compound (Z)-3'-~arboxyl-2~enzyliden~5-
~hla~obenzofur~n-3-(2~ e, and simil~r formul~tions c~n be prepared with other
solid compounds of the invention.
E~AMPLE ~9
,__
~3:nrd gelntin capsules were prepared l~ing the Iollowing in~redients:




Aetive ~ompound ~SO
~ dried 200
Magnesium s~enrate 10
The above indredients we~e mi~ nd fiUed into hard gelatin cap~sule~s
EXAMPLE 70
A tablet fo~mula w~s prepared using the ingredients below:



Active compound 250
Ce~ulo6e miero~rystalline 400
Silicon clioxide ~umed 10

Stearic acid 5


, ~ ~
* Trademark

P~3~
.~ .
26-


The components were blended and compre~ed to form tablets.
A~flPLE 71
An &erosol solutir~ wns prepOEed containing the following components:

W~%
Active ingredient0.25
~th~Dol 29.75
" Propellant 22 " *70
( Chlorodi~luorom ethQzle)
ll~e active compo~d was mixed with ethanol and the mixture added to thç
propell~nt 22, cooled to -30C and ~an~ferred to a filling deYiceO The required
amount was then ~ed to a stainles~ steel containe~ and diluted further with a
metered amount of propellant. The valve uni~ were then fitted to the container.
EXAMPL~. 72
A suppository formula wa~ prepared containing 200 mg OI t~ compound usinK the
~ollowing ingredients:
Acti-.re eompound 200 mg
Polyethylene glycol 1000 750 mg
Polyethylene gly~ol 4000 250 mg
The activ~ compound was mi~:ed in ~he molten glycol base~ and then the mixt~re was
poured intn apl?ropriate suppository moulds~ to give the active f~l weight.
E~A~qPL13 73
An ointm~t w~s made to the i~ollowing fo~mula:
Active compound 1% by wei~ht
White soft p~rafin up to 1û0%
The activ~ compound wa~ added to tlle mol~en paraffin Qnd th~n the mixtur~ was
a310~ed to co~l.



* Trademark

Representative Drawing

Sorry, the representative drawing for patent document number 1202309 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date 1986-03-25
(22) Filed 1979-09-12
(45) Issued 1986-03-25
Expired 2003-03-25

Abandonment History

There is no abandonment history.

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Application Fee $0.00 1979-09-12
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
LILLY INDUSTRIES LIMITED
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Drawings 1993-06-24 1 9
Claims 1993-06-24 7 161
Abstract 1993-06-24 1 23
Cover Page 1993-06-24 1 18
Description 1993-06-24 26 1,073